Charles Schwab Investment Management Inc. Purchases 100,586 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Charles Schwab Investment Management Inc. grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 27.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 472,028 shares of the company’s stock after buying an additional 100,586 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.83% of Harmony Biosciences worth $16,242,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HRMY. Citigroup Inc. increased its stake in Harmony Biosciences by 9.8% in the 3rd quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock worth $7,114,000 after buying an additional 15,859 shares during the period. HighTower Advisors LLC increased its position in shares of Harmony Biosciences by 364.0% during the third quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock worth $3,199,000 after purchasing an additional 62,729 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Harmony Biosciences by 68.4% in the third quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock valued at $9,217,000 after buying an additional 93,622 shares during the last quarter. StoneX Group Inc. purchased a new stake in Harmony Biosciences during the 3rd quarter worth approximately $755,000. Finally, Barclays PLC increased its position in shares of Harmony Biosciences by 110.9% in the 3rd quarter. Barclays PLC now owns 76,862 shares of the company’s stock valued at $3,074,000 after acquiring an additional 40,416 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

HRMY stock opened at $34.90 on Friday. Harmony Biosciences Holdings, Inc. has a 1 year low of $28.14 and a 1 year high of $41.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. The firm has a market capitalization of $2.00 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The business has a 50 day simple moving average of $36.39 and a 200-day simple moving average of $35.60.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $201.30 million during the quarter, compared to analysts’ expectations of $201.25 million. During the same period in the prior year, the business earned $0.45 EPS. The firm’s quarterly revenue was up 19.5% on a year-over-year basis. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HRMY shares. Mizuho boosted their price objective on Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a report on Tuesday, February 25th. Finally, HC Wainwright decreased their price objective on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $53.33.

Insider Buying and Selling

In related news, CFO Sandip Kapadia sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total value of $388,864.07. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,452 shares of company stock worth $2,831,679. Insiders own 30.80% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.